Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine

Journal of Psychiatric Research

Volumn 45, Issue 6, 2011, Pages 763-769

  Crespo Facorro, Benedicto ^a,c   Pérez Iglesias, Rocío ^b,c   Mata, Ignacio ^b,c   Caseiro, Olalla ^b   Martínez Garcia, Obdulia ^b   Pardo, Gema ^b   Ramirez Bonilla, MariLuz ^b   Pelayo Terán, Jose Maria ^b   Vázquez Barquero, José L ^a,c  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Antipsychotics; Clinical practice; Open label; Schizophrenia; Treatment

Indexed keywords

HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENTAL CAPACITY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REMISSION; SPAIN; UNIVERSITY HOSPITAL;

EID: 79955920322     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2010.11.002     Document Type: Article

References (31)

1. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 2005, 162(3):441-449.
2. Boter H., Peuskens J., Libiger J., Fleischhacker W.W., Davidson M., Galderisi S., et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophrenia Research 2009, 115:97-103. EUFEST Study Group.
3. Crespo-Facorro B., Pérez-Iglesias R., González-Blanch C., Mata I. Treatment of the first episode of schizophrenia: an update on pharmacologic and psychological interventions. Current Psychiatry Report 2008, 10(3):202-209.
4. Crespo-Facorro B, Perez-Iglesias R, Mata I, Ramirez-Bonilla ML, Martinez-Garcia O, Pardo-Garcia G, et al. Effectiveness and efficacy of haloperidol, risperidone and olanzapine in the treatment of first-episode nonaffective psychosis: results of a randomized, controlled 1-year follow-up comparison. Journal of Psychopharmacology, In press.
5. Craig T.K., Garety P., Power P., Rahaman N., Colbert S., Fornells-Ambrojo M., et al. The Lambeth Early Onset (LEO) team: randomised controlled trial of the effectiveness of specialised care for early psychosis. British Medical Journal 2004, 329(7474):1067.
6. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 2002, 346:16-22.
7. DeQuardo J.R., Tandon R. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?. Journal of Psychiatric Research 1998, 32:229-242.
8. Dossenbach M., Arango-Dávila C., Silva Ibarra H., Landa E., Aguilar J., Caro O., et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Journal of Clinical Psychiatry 2005, 66(8):1021-1030.
9. Emsley R., Rabinowitz J., Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophrenia Research 2007, 89:129-139.
10. First M.B., Gibbon M., Williams J. Structured clinical interview for DSM-IV-TR Axis I disorders- non patient edition 2001, New York State Psychiatric Institute, New York.
11. Gilbert P.L., Harris M.J., McAdams L.A., Jeste D.V. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry 1995, 52(3):173-188.
12. Gleeson J.F., Alvarez-Jimenez M., Cotton S.M., Parker A.G., Hetrick S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophrenia Research 2010, 119(1-3):79-88.
13. ECDEU assessment manual for psychopharmacology. US department of health, education, and welfare publication ADM 76338 1976, 217-222. National Institute of Mental Health, Washington, DC. W. Guy (Ed.).
14. Herz M.I., Lamberti J.S., Mintz J., Scott R., O'Dell S.P., McCartan L., et al. A program for relapse prevention in schizophrenia: a controlled study. Archives of General Psychiatry 2000, 57(3):277-283.
15. Hogarty G.E., Ulrich R.F. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. Journal of Psychiatric Research 1998, 32(3-4):243-250.
16. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
17. Leucht S., Barnes T.R.E., Kissling W., Engel R.R., Correll C., Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry 2003, 160(7):1209-1222.
18. Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology May 2003, 28(5):995-1003.
19. Linszen D., Lenior M., De Haan L., Dingemans P., Gersons B. Early intervention, untreated psychosis and the course of early schizophrenia. British Journal of Psychiatry (Supplement) 1998, 172(33):84-89.
20. Malla A., Norman R., Bechard-Evans L., Schmitz N., Manchanda R., Cassidy C. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychological Medicine 2008, 38(11):1585-1593.
21. Malla A., Norman R., Schmitz N., Manchanda R., Béchard-Evans L., Takhar J., et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychological Medicine 2006, 36(5):649-658.
22. March J.S., Silva S.G., Compton S., Shapiro M., Califf R., Krishnan R. The case for practical clinical trials in psychiatry. American Journal of Psychiatry 2005, 162:836-846.
23. Marder S.R., Glynn S.M., Wirshing W.C., Wirshing D.A., Ross D., Widmark C., et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. American Journal of Psychiatry 2003, 160(8):1405-1412.
24. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychological Reports 1962, 10:799-812.
25. Pelayo-Teran J.M., Perez-Iglesias R., Ramirez-Bonilla M.L., Gonzalez-Blanch C., Martinez-Garcia O., Pardo-Garcia G., et al. Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the PAFIP. Early Intervention in Psychiatry 2008, 2:178-187.
26. Ram R., Bromet E.J., Eaton W.W., Pato C., Schwartz J.E. The natural course of schizophrenia: a review of first-admission studies. Schizophrenia Bulletin 1992, 18(2):185-207.
27. Robinson D.G., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 1999, 56(3):241-270.
28. Robinson D.G., Woerner M.G., McMeniman M., Mendelowitz A., Bilder R.M. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2004, 161(3):473-490.
29. Schooler N., Rabinowitz J., Davidson M., Emsley R., Harvey P.D., Kopala L., et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomised trial. American Journal of Psychiatry 2005, 162:947-953.
30. van Os J., Burns T., Cavallaro R., Leucht S., Peuskens J., Helldin L., et al. Standardized remission criteria in schizophrenia. Acta Psychiatrica Scandinavica 2006, 113:91-95.
31. Wyatt R.L. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin 1991, 17:325-351.